Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence

Physiology & Behavior(2024)10.1016/j.physbeh.2024.114565Source: DataRank Database

Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence is a research paper published in Physiology & Behavior (2024). On theSindex it has a DataRank of 1.2. It has been cited 42 times, with 40 citing works in its 1-hop citation network.

N/A

1.2DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access42 citations · 40 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT05610800

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 8.03)OA: greenTopics (33)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 46%Citation Network 54%

Base Score Contribution

0.564

From this paper's citation signal

Citation Network Contribution

0.650

From 20 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 40 citers.

Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!
Expert Review of Clinical Pharmacology20246 citations14 referencesContributes 0.139
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial
The Lancet202611 citations28 referencesContributes 0.089
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
JAMA Psychiatry2025207 citations64 referencesContributes 0.083
Modulating reward circuits through GLP-1 signaling: implications for behavioral and substance addictions
Psychopharmacology20252 citations14 referencesContributes 0.078
The brain geography of GLP-1: An atlas for a new era
Brain medicine :20261 citations15 referencesContributes 0.046

Authors (2)

Heath D. Schmidt ORCID,Rae J. Herman ORCID

Live enrichment

PubMed:38663460 OpenAlex:https://openalex.org/W4395053663

NIDA

Grant: R01 DA037897

NIDA

Grant: R21 DA045792

NIDA

Grant: T32 DA028874

NIDA

Grant: F31 DA058451

FWCI

8.03

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11128349/pdf/nihms-1991125.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0031938424001100?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0031938424001100?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11128349

Fields of Study

Neuropeptides and Animal PhysiologyReceptor Mechanisms and SignalingNicotinic Acetylcholine Receptors StudyHumansTobacco Use DisorderAnimalsSubstance Withdrawal SyndromeSmoking CessationNicotineGlucagon-Like Peptide-1 Receptor Agonists

MeSH Terms

Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsAnimalsHumansNicotineSubstance Withdrawal SyndromeTobacco Use DisorderSmoking Cessation

Keywords

NicotineNicotine withdrawalMedicineSmoking cessationAbstinenceWeight gainInternal medicinePsychiatryBody weightHyperphagiaRelapseSelf-administrationSemaglutideSmokingWithdrawal

Sustainable Development Goals

SDG 0: Good health and well-being